OIS Podcast Ep

In this episode of The Rob and Jai Show from OIS XIV, hosts Dr. Rob Rothman and Dr. Jai Parekh talk with Eric Schlumpf, CEO of Stuart Therapeutics, about the company’s transformative approach to ophthalmic diseases. Learn how Stuart's innovative polypeptide technology repairs damaged collagen, advancing from dry eye to neuroprotection in glaucoma and beyond. Eric highlights key milestones, including promising clinical trial results, strategic partnerships, and the company’s plans to tackle major unmet needs like myopia and inherited retinal diseases.

In this episode, you’ll learn:
🔹How Stuart Therapeutics’ polypeptide platform is revolutionizing ophthalmic treatments.
🔹The potential for neuroprotection in glaucoma and what makes Stuart’s approach unique.
🔹Why Stuart’s dry eye clinical program could be a market differentiator.
🔹The exciting data supporting new indications like myopia and inherited retinal disease.
🔹How strategic partnerships are fueling innovation in a capital-efficient way.

Website:
https://ois.net

FOLLOW Ophthalmology Innovation Source On Social Media:
► LinkedIn:   / ois-net  
► Twitter:   / oistweets  

JOIN Our Group For Ophthalmology Innovation & Investment On LinkedIn
  / 2189664  

SUBSCRIBE To Our Weekly OIS Newsletter
http://bit.ly/2yFOXUt

VIEW Our Past Ophthalmology Event Conferences:
https://ois.net/past-events

REGISTER For Our Next Meeting:
https://ois.net/ois-events

#OIS #Ophthalmology #Healthcare #Ophthalmic #Medicalinnovation #Retina #Eyediseases

_________________________________________________________________

About OIS

Ophthalmology Innovation Summit (OIS) facilitates meaningful interactions and the exchange of information between clinical, capital, and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.

Since 2009, the Ophthalmology Innovation Summit programs are independently produced conferences presented annually by Healthegy, Inc.